Jennison Associates
PHAT icon

Jennison Associates’s Phathom Pharmaceuticals PHAT Stock Holding History

Jennison Associates’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-7,042,325
Closed -$44.2M – 623
2025
Q1 		$44.2M Sell
7,042,325
-20,182
-0.3% -$123K 0.03% 231
2024
Q4 		$57.3M Buy
7,062,507
+1,196,118
+20% +$14.8M 0.03% 210
2024
Q3 		$106M Buy
5,866,389
+3,108,810
+113% +$43.5M 0.07% 132
2024
Q2 		$28.4M Buy
2,757,579
+1,109,882
+67% +$11.4M 0.02% 295
2024
Q1 		$17.5M Buy
+1,647,697
New +$14M 0.01% 353

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Jennison Associates's PHAT Position: Q2 2025 in Review

Jennison Associates sold out of Phathom Pharmaceuticals (PHAT) in Q2 2025, closing a stake of 7,042,325 shares — an estimated $44.2M sold.

Jennison Associates first reported a position in PHAT in Q1 2024 and held it in 5 quarters. The position peaked at $106M in Q3 2024. 117 funds tracked by Wall St. Rank hold PHAT as of Q2 2025.

  • Jennison Associates reported no remaining Phathom Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Jennison Associates sold 7,042,325 Phathom Pharmaceuticals shares in Q2 2025, an estimated $44.2M.
  • Jennison Associates first reported a position in Phathom Pharmaceuticals in Q1 2024 and held it in 5 quarters.
  • Jennison Associates's Phathom Pharmaceuticals position peaked at $106M in Q3 2024.
  • 117 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2025.

Based on Jennison Associates's 13F filing for Q2 2025, filed 1 Aug 2025.